Back to Search Start Over

Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients.

Authors :
Lichtensteiger C
Koblischke M
Berner F
Jochum AK
Sinnberg T
Balciunaite B
Purde MT
Walter V
Abdou MT
Hofmeister K
Kohler P
Vernazza P
Albrich WC
Kahlert CR
Zoufaly A
Traugott MT
Kern L
Pietsch U
Kleger GR
Filipovic M
Kneilling M
Cozzio A
Pop O
Bomze D
Bergthaler A
Hasan Ali O
Aberle J
Flatz L
Source :
Journal of autoimmunity [J Autoimmun] 2023 Nov; Vol. 140, pp. 103118. Date of Electronic Publication: 2023 Oct 10.
Publication Year :
2023

Abstract

Background: The role of autoreactive T cells on the course of Coronavirus disease-19 (COVID-19) remains elusive. Type II pneumocytes represent the main target cells of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Autoimmune responses against antigens highly expressed in type II pneumocytes may influence the severity of COVID-19 disease.<br />Objective: The aim of this study was to investigate autoreactive T cell responses against self-antigens highly expressed in type II pneumocytes in the blood of COVID-19 patients with severe and non-severe disease.<br />Methods: We collected blood samples of COVID-19 patients with varying degrees of disease severity and of pre-pandemic controls. T cell stimulation assays with peptide pools of type II pneumocyte antigens were performed in two independent cohorts to analyze the autoimmune T cell responses in patients with non-severe and severe COVID-19 disease. Target cell lysis assays were performed with lung cancer cell lines to determine the extent of cell killing by type II PAA-specific T cells.<br />Results: We identified autoreactive T cell responses against four recently described self-antigens highly expressed in type II pneumocytes, known as surfactant protein A, surfactant protein B, surfactant protein C and napsin A, in the blood of COVID-19 patients. These antigens were termed type II pneumocyte-associated antigens (type II PAAs). We found that patients with non-severe COVID-19 disease showed a significantly higher frequency of type II PAA-specific autoreactive T cells in the blood when compared to severely ill patients. The presence of high frequencies of type II PAA-specific T cells in the blood of non-severe COVID-19 patients was independent of their age. We also found that napsin A-specific T cells from convalescent COVID-19 patients could kill lung cancer cells, demonstrating the functional and cytotoxic role of these T cells.<br />Conclusions: Our data suggest that autoreactive type II PAA-specific T cells have a protective role in SARS-CoV-2 infections and the presence of high frequencies of these autoreactive T cells indicates effective viral control in COVID-19 patients. Type II-PAA-specific T cells may therefore promote the killing of infected type II pneumocytes and viral clearance.<br /> (Copyright © 2023 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1095-9157
Volume :
140
Database :
MEDLINE
Journal :
Journal of autoimmunity
Publication Type :
Academic Journal
Accession number :
37826919
Full Text :
https://doi.org/10.1016/j.jaut.2023.103118